Inching Closer

Patients enrolled in a phase III trial of a novel Bcl-2-directed antisense agent plus chemotherapy with dacarbazine (DTIC) are yielding remarkable responses thus far, according to Anna C. Pavlick, D.O., assistant professor of medicine, New York University School of Medicine, New York.

Related Videos
Related Content

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

POLL: What Topics Did You Most Enjoy at AAD 2023?

March 27th 2023

Lanolin Named Allergen of the Year

March 27th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

POLL: What Topics Did You Most Enjoy at AAD 2023?

March 27th 2023

Lanolin Named Allergen of the Year

March 27th 2023

Recent Povorcitinib 2b Study Shows Improved Repigmentation

March 27th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD

March 27th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

POLL: What Topics Did You Most Enjoy at AAD 2023?

March 27th 2023

Lanolin Named Allergen of the Year

March 27th 2023
© 2023 MJH Life Sciences

All rights reserved.